<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300455</url>
  </required_header>
  <id_info>
    <org_study_id>4305-036</org_study_id>
    <nct_id>NCT01300455</nct_id>
  </id_info>
  <brief_title>Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)</brief_title>
  <official_title>A Study to Evaluate the Effects of MK-4305 in Patients With Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant
      (MK-4305) on respiratory function in participants with mild to moderate obstructive sleep
      apnea (OSA) compared to administration of placebo. The primary hypothesis of this study is
      that multiple doses of MK-4305 do not produce a clinically significant increase in
      Apnea-Hypopnea Index (AHI) in participants with mild to moderate OSA, as compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2011</start_date>
  <completion_date type="Actual">August 11, 2011</completion_date>
  <primary_completion_date type="Actual">August 11, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Apnea-Hypopnea Index (AHI)</measure>
    <time_frame>Day 4</time_frame>
    <description>Evaluation of the effect of multiple dose administration of suvorexant on
AHI as measured by polysomnography. The AHI is an overall index of obstructive sleep apnea (OSA) severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Adverse Event</measure>
    <time_frame>Up to 14 days after last dose</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to an AE</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Evaluation of the effect of multidose dose suvorexant on mean SaO2 during total sleep time as measured by pulse oximetry. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Total Sleep Time That Arterial SaO2 is Less Than 90%, 85%, and 80%</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Evaluation of the percentage of the night in which SaO2 is less than 90%, less
than 85% and less than 80% following multiple dose administration of
suvorexant and placebo. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial SaO2 for Different Sleep Stages</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Comparison of the mean SaO2 during different sleep stages (REM, Non-REM, and awake) following multiple dose administration of suvorexant and placebo. Sleep stages were determined by polysomnography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AHI</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of the effect of multiple dose administration of suvorexant on
AHI as measured by polysomnography. The AHI is an overall index of OSA severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Suvorexant (40 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1, suvorexant (40 mg tablets) administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Period 1, placebo administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered once daily for 4 consecutive days in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>40 mg tablets, orally once daily for 4 consecutive days in the evening</description>
    <arm_group_label>Suvorexant (40 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>MK-4305</other_name>
    <other_name>SCH 900433</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Placebo tablets, orally once daily for 4 consecutive days in the evening</description>
    <arm_group_label>Suvorexant (40 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female participants of reproductive potential must demonstrate a serum β-human
             chorionic gonadotrophin (hCG) level consistent with the nongravid state at the
             pre-study (screening) visit and agree to use (and/or have their partner use) two (2)
             acceptable methods of birth control beginning at the pre-study visit throughout the
             study.

          -  Women who are postmenopausal without menses for at least 1 year and a follicle
             stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening)
             evaluation, and/or are status post hysterectomy, oophorectomy or tubal ligation may
             participate.

          -  Participants with a Body Mass Index (BMI) ≤40 kg/m2 at the pre-study (screening)
             visit.

          -  Participants have to be in good health based on medical history, physical examination,
             vital sign measurements, and laboratory safety tests.

          -  Participants without clinically significant abnormality on electrocardiogram (ECG)
             performed at the pre-study (screening) visit and/or prior to administration of the
             initial dose of study drug.

          -  Participants have an International Classification of Sleep Disorders diagnosis of OSA.

          -  Participants have confirmed mild or moderate OSA (defined as mild

        OSA with AHI ≥5 and &lt;15, and moderate OSA with AHI ≥15 and &lt;30) based on the screening
        nighttime polysomnography (NPSG).

          -  Participants have a usual bedtime between 20:00 (8:00 post meridiem [PM]) and 00:30
             (12:30 ante meridiem [AM)] and is not subject to any other unusual changes in sleeping
             routine and sleeps for 4 hours or more per night.

          -  Participants must complete a sleep history diary for at least 5 consecutive days and
             up to 21 days prior to the screening PSG visit.

          -  Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing
             products for at least approximately 6 months; participants who have discontinued
             smoking or the use of nicotine/nicotine containing products for at least approximately
             3 months may be enrolled in the study at the discretion of the investigator.

        Exclusion Criteria:

          -  Participants have used continuous positive airway pressure devise (CPAP) or a dental
             appliance within the preceding 7 days prior to screening NPSG Visit, or is required to
             use CPAP or a dental appliance during course of the study (7 days prior to the
             screening NPSG, throughout the study [including washout intervals between treatment
             periods], and until the poststudy visit).

          -  Participants have other than OSA and evidence of another clinically significant,
             active pulmonary disorder such as bronchiectasis, emphysema, or asthma documented by
             history, physical examination, or chest x‑ray.

          -  Participant have either a history within the past 6 months prior to the prestudy visit
             or current evidence of an unstable or clinically significant cardiovascular disorder,
             including but not limited to acute coronary syndrome, unstable angina, congestive
             heart failure, cardiogenic syncope, cardiomyopathy, any symptomatic arrhythmia,
             orthostatic hypotension, or uncontrolled hypertension.

          -  Participants have abnormal pre-randomization laboratory values other clinically
             significant, unexplained laboratory abnormality in the opinion of the investigator
             with alanine transaminase (ALT) &gt;1.5 x the upper limit of normal (x ULN), aspartate
             transaminase (AST) &gt;1.5 x ULN, total bilirubin &gt;1.5 x ULN, or serum creatinine of &gt;2
             mg/dL.

          -  Participants have a history or diagnosis of narcolepsy, cataplexy (familial or
             idiopathic), circadian rhythm sleep disorder, parasomnia including nightmare disorder,
             sleep terror disorder, sleepwalking disorder, and REM behavior disorder, periodic limb
             movement (PLM) disorder, restless legs syndrome, or primary hypersomnia.

          -  Participants have a screening PSG recording with oxygen (O2) saturation &lt;80% for ≥5%
             of the total sleep time, and &gt;10 PLM per hour associated with an arousal (periodic
             limb movement arousal index [PLMAI]).

          -  Participant is mentally or legally incapacitated, has significant emotional problems
             at the time of prestudy (screening) visit or expected during the conduct of the study
             or has a history of a clinically significant psychiatric disorder over the last 5 to
             10 years. Participant who have had situational depression may be enrolled in the study
             at the discretion of the investigator.

          -  Participant has lifetime history of bipolar disorder, a psychotic disorder, or
             posttraumatic stress disorder; or, a psychiatric condition requiring treatment with a
             prohibited medication; or, other psychiatric condition that, in the investigator's
             opinion, would interfere with the participant's ability to participate in the study.

          -  Participant, in the opinion of the investigator, has a history or current evidence of
             any condition, therapy, lab or ECG abnormality or other circumstances that might
             confound the results of the study, or interfere with the participant's participation
             for the full duration of the study.

          -  Participant has any history of a neurological disorder, including but not limited to
             seizure disorder (other than single episodes of childhood febrile seizures), stroke,
             transient ischemic attack, multiple sclerosis, cognitive impairment, or significant
             head trauma with sustained loss of consciousness within the last 10 years.

          -  Participant has a history of clinically significant endocrine, gastrointestinal,
             cardiovascular, hematological, hepatic, immunological, renal, respiratory, or
             genitourinary abnormalities or diseases. Participants with a history of uncomplicated
             kidney stones may be enrolled in the study at the discretion of the investigator.

          -  Participant has a history of neoplastic disease except: 1. adequately treated
             non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate in
             the study; 2. participants with other malignancies which have been successfully
             treated ≥10 years prior to the prestudy (screening) visit where, in the judgment of
             both the Investigator and treating physician, appropriate follow-up has revealed no
             evidence of recurrence from the time of treatment through the time of the prestudy
             (screening) visit, or 3. participants, who, in the opinion of the Investigator, are
             highly unlikely to sustain a recurrence for the duration of the study.

          -  Participant is a nursing mother.

          -  Participant has a positive screening urine alcohol test or drug test.

          -  Participant has a need for more than 3 toilet visits during the night.

          -  Participant is taking, or plans to take, one or more of prohibited concomitant
             medication.

          -  Participant consumes excessive amounts of alcohol (greater than 3 glasses of alcoholic
             beverages), excessive amounts of coffee, tea, cola, or other caffeinated beverages per
             day.

          -  Participant has had major surgery, donated or lost 1 unit of blood (approximately 500
             mL) or participated in another investigational study within 4 weeks prior to the
             prestudy (screening) visit.

          -  Participant has a history of significant multiple and/or severe allergies (including
             latex allergy), or has had an anaphylactic reaction or significant intolerability to
             prescription or non-prescription drugs or food.

          -  Participant is currently a regular user (including &quot;recreational use&quot;) of any illicit
             drugs or has a history of drug (including alcohol) abuse within approximately 2 years.

          -  Participant works a night shift and is not able to avoid night shift work within 2
             weeks before each treatment visit (or before the study start and during the study).

          -  Participant has traveled across 3 or more time zones (transmeridian travel) in the
             last 1 week prior to study start.

          -  Participant is at imminent risk of self-harm or harm to others

          -  Any concern by the investigator regarding the safe participation of the participant in
             the study or for any other reason; the investigator considers the participant
             inappropriate for participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med. 2016 Jan;12(1):9-17. doi: 10.5664/jcsm.5382.</citation>
    <PMID>26194728</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <results_first_submitted>August 19, 2014</results_first_submitted>
  <results_first_submitted_qc>August 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>orexin receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=4305-036&amp;kw=4305-036&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Suvorexant (40 mg) Then Placebo</title>
          <description>In Period 1, suvorexant (40 mg tablets) administered orally, once daily, for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Suvorexant (40 mg)</title>
          <description>Period 1 consists of placebo administered once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered orally, once daily, for 4 consecutive days in the evening.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Suvorexant (40 mg) Then Placebo</title>
          <description>In Period 1, Suvorexant (40 mg tablets) administered orally, once daily, for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then Suvorexant (40 mg)</title>
          <description>Period 1 consists of placebo administered once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, Suvorexant (40 mg tablets) administered orally, once daily, for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="34" upper_limit="63"/>
                    <measurement group_id="B2" value="50" lower_limit="30" upper_limit="64"/>
                    <measurement group_id="B3" value="49" lower_limit="30" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Apnea-Hypopnea Index (AHI)</title>
        <description>Evaluation of the effect of multiple dose administration of suvorexant on
AHI as measured by polysomnography. The AHI is an overall index of obstructive sleep apnea (OSA) severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
        <time_frame>Day 4</time_frame>
        <population>Twenty-five of 26 participants had Day 4 data; one participant did not receive placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Apnea-Hypopnea Index (AHI)</title>
          <description>Evaluation of the effect of multiple dose administration of suvorexant on
AHI as measured by polysomnography. The AHI is an overall index of obstructive sleep apnea (OSA) severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
          <population>Twenty-five of 26 participants had Day 4 data; one participant did not receive placebo.</population>
          <units>Events per hour</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.07" lower_limit="13.30" upper_limit="20.84"/>
                    <measurement group_id="O2" value="14.41" lower_limit="10.61" upper_limit="18.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.66</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Adverse Event</title>
        <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
        <time_frame>Up to 14 days after last dose</time_frame>
        <population>All participants were included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event</title>
          <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
          <population>All participants were included in the Safety Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
        <description>An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
        <time_frame>Up to 13 days</time_frame>
        <population>All participants were included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
          <description>An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
          <population>All participants were included in the Safety Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time</title>
        <description>Evaluation of the effect of multidose dose suvorexant on mean SaO2 during total sleep time as measured by pulse oximetry. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
        <time_frame>Day 1 and Day 4</time_frame>
        <population>Twenty-four of 26 participants were included in the primary evaluation of Day 1 AHI/SaO2 data; 2 participants had no data due to either not receiving placebo or an equipment malfunction. Twenty-five of 26 participants had Day 4 data; one participant did not receive placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time</title>
          <description>Evaluation of the effect of multidose dose suvorexant on mean SaO2 during total sleep time as measured by pulse oximetry. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
          <population>Twenty-four of 26 participants were included in the primary evaluation of Day 1 AHI/SaO2 data; 2 participants had no data due to either not receiving placebo or an equipment malfunction. Twenty-five of 26 participants had Day 4 data; one participant did not receive placebo.</population>
          <units>Percentage of Oxygen Saturation</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n = 26, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.12" lower_limit="93.48" upper_limit="94.75"/>
                    <measurement group_id="O2" value="94.15" lower_limit="93.50" upper_limit="94.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n = 26, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.15" lower_limit="93.53" upper_limit="94.78"/>
                    <measurement group_id="O2" value="94.21" lower_limit="93.59" upper_limit="94.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Total Sleep Time That Arterial SaO2 is Less Than 90%, 85%, and 80%</title>
        <description>Evaluation of the percentage of the night in which SaO2 is less than 90%, less
than 85% and less than 80% following multiple dose administration of
suvorexant and placebo. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.</description>
        <time_frame>Day 1 and Day 4</time_frame>
        <population>Twenty-four of 26 participants were included in the primary evaluation of Day 1 AHI/SaO2 data; 2 participants had no data due to either not receiving placebo or an equipment malfunction. Twenty-five of 26 participants had Day 4 data; one participant did not receive placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Sleep Time That Arterial SaO2 is Less Than 90%, 85%, and 80%</title>
          <description>Evaluation of the percentage of the night in which SaO2 is less than 90%, less
than 85% and less than 80% following multiple dose administration of
suvorexant and placebo. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.</description>
          <population>Twenty-four of 26 participants were included in the primary evaluation of Day 1 AHI/SaO2 data; 2 participants had no data due to either not receiving placebo or an equipment malfunction. Twenty-five of 26 participants had Day 4 data; one participant did not receive placebo.</population>
          <units>Percentage of Total Sleep Time</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (SaO2 is less than 90%) (n = 26, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" lower_limit="1.03" upper_limit="5.58"/>
                    <measurement group_id="O2" value="2.57" lower_limit="0.22" upper_limit="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (SaO2 is less than 85%) (n = 26, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.12" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.24" lower_limit="-0.14" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (SaO2 is less than 80%) (n = 26, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to the small number of participants experiencing SaO2 less than 80%, a formal statistical analysis was not conducted.</measurement>
                    <measurement group_id="O2" value="NA">Due to the small number of participants experiencing SaO2 less than 80%, a formal statistical analysis was not conducted.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (SaO2 is less than 90%) (n = 26, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" lower_limit="0.88" upper_limit="3.45"/>
                    <measurement group_id="O2" value="1.95" lower_limit="0.66" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (SaO2 is less than 85%) (n = 26, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.16" upper_limit="1.23"/>
                    <measurement group_id="O2" value="0.41" lower_limit="-0.13" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (SaO2 is less than 80%) (n = 26, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to the small number of participants experiencing SaO2 less than 80%, a formal statistical analysis was not conducted.</measurement>
                    <measurement group_id="O2" value="NA">Due to the small number of participants experiencing SaO2 less than 80%, a formal statistical analysis was not conducted.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, SaO2 &lt;90%, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, SaO2 &lt;85%, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, SaO2 &lt;90%, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, SaO2 &lt;85%, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial SaO2 for Different Sleep Stages</title>
        <description>Comparison of the mean SaO2 during different sleep stages (REM, Non-REM, and awake) following multiple dose administration of suvorexant and placebo. Sleep stages were determined by polysomnography.</description>
        <time_frame>Day 1 and Day 4</time_frame>
        <population>Twenty-four of 26 participants were included in the primary evaluation of Day 1 AHI/SaO2 data; 2 participants had no data due to either not receiving placebo or an equipment malfunction. Twenty-five of 26 participants had Day 4 data; one participant did not receive placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial SaO2 for Different Sleep Stages</title>
          <description>Comparison of the mean SaO2 during different sleep stages (REM, Non-REM, and awake) following multiple dose administration of suvorexant and placebo. Sleep stages were determined by polysomnography.</description>
          <population>Twenty-four of 26 participants were included in the primary evaluation of Day 1 AHI/SaO2 data; 2 participants had no data due to either not receiving placebo or an equipment malfunction. Twenty-five of 26 participants had Day 4 data; one participant did not receive placebo.</population>
          <units>Percentage of Oxygen Saturation</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 - Mean SaO2 During REM (n = 26, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.08" lower_limit="93.34" upper_limit="94.82"/>
                    <measurement group_id="O2" value="94.14" lower_limit="93.38" upper_limit="94.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Mean SaO2 during Non-REM (n = 26, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.12" lower_limit="93.47" upper_limit="94.76"/>
                    <measurement group_id="O2" value="94.07" lower_limit="93.41" upper_limit="94.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Mean SaO2 during Wake (n = 26, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.42" lower_limit="93.74" upper_limit="95.11"/>
                    <measurement group_id="O2" value="94.94" lower_limit="94.23" upper_limit="95.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 - Mean SaO2 During REM (n = 26, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.96" lower_limit="93.17" upper_limit="94.76"/>
                    <measurement group_id="O2" value="93.83" lower_limit="93.03" upper_limit="94.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 - Mean SaO2 during Non-REM (n = 26, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.27" lower_limit="93.64" upper_limit="94.90"/>
                    <measurement group_id="O2" value="94.25" lower_limit="93.62" upper_limit="94.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 - Mean SaO2 during Wake (n = 26, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.73" lower_limit="94.11" upper_limit="95.36"/>
                    <measurement group_id="O2" value="94.91" lower_limit="94.28" upper_limit="95.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, REM, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Non-REM, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Wake, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, REM, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, Non-REM, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, Wake, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean AHI</title>
        <description>Evaluation of the effect of multiple dose administration of suvorexant on
AHI as measured by polysomnography. The AHI is an overall index of OSA severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
        <time_frame>Day 1</time_frame>
        <population>Twenty-four of 26 participants were included in the primary evaluation of Day 1 AHI/SaO2 data; 2 participants had no data due to either not receiving placebo or an equipment malfunction.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean AHI</title>
          <description>Evaluation of the effect of multiple dose administration of suvorexant on
AHI as measured by polysomnography. The AHI is an overall index of OSA severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
          <population>Twenty-four of 26 participants were included in the primary evaluation of Day 1 AHI/SaO2 data; 2 participants had no data due to either not receiving placebo or an equipment malfunction.</population>
          <units>Events per hour</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.25" lower_limit="12.65" upper_limit="19.86"/>
                    <measurement group_id="O2" value="16.72" lower_limit="13.02" upper_limit="20.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.20</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Suvorexant (40 mg)</title>
          <description>Participants administered a 40-mg dose of suvorexant.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants administered placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

